Show Me the Money: Why Companies Overpay MCOs--and How They Can Stop
Executive Summary
To get on formularies, drug companies pay MCOs too much in rebates and get too little market share in return. But "fair share" analysis can help yield big revenue gains as well as giving drug companies the tools to make business-improving tradeoffs within their product portfolios. Key analyses and related interventions can help return to manufacturers some of the market power and negotiating leverage that is shifting from pharma companies to MCOs.
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.